LGALS3 and Hodgkins lymphoma: Tumor cell expression of Gal-3 has also been associated with poor prognosis in non-small-cell lung cancer (201), Hodgkin lymphoma (202), and acute myeloid leukemia (203), but the opposite effect has also been reported for breast (204) and gastric (205) cancer.